A graduate of ENS, one of France’s most prestigious Grandes Écoles, Cyrille Pauthenier was only 26 when he launched Abolis while completing his thesis at the Institute of Systems & Synthetic Biology (University of Évry-Paris Saclay).
Step by step, with his double researcher/entrepreneur profile and the discipline and energy that go with it, Cyrille grew his innovative and potential-filled start-up. He earned numerous distinctions along the way, including winning the “Technological Potential” prize in the 2013 Genopole Young Biotech Award and being a laureate of Phase 2 of the French State’s Global Innovation Competition 2030.
In Abolis and the field of synthetic biology, Cyrille sees an alternative, more ecological and bio-based path toward industrial production. With its disruptive technology built on a foundation of genetics, mathematics and informatics, his company conceives microorganisms (yeasts, bacteria, etc.) able to produce compounds of interest in industry, food & agriculture, cosmetics, pharmacology and more.
Today, Abolis is a renowned and trusted partner for industrials. The groups Bel and Lesaffre are working by Abolis’ side within the Metapath project, financed by the Investments for the Future program, to “conceive healthier and more-natural food products.”
Having attracted the attention of a wide range of markets, Cyrille Pauthenier is launching ambitious projects for Abolis, and growing the teams and infrastructures he needs to make them real at Genopole.
